Adbry and Aortogram abnormal - a phase IV clinical study of FDA data
Summary:
We study 1,908 people who take Adbry (tralokinumab) or have Aortogram abnormal. No report of Aortogram abnormal is found in people who take Adbry.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
What is Adbry?
Adbry has active ingredients of tralokinumab. eHealthMe is studying from 1,899 Adbry users. Check the latest studies of Adbry.
What is Aortogram Abnormal?
Aortogram abnormal is found to be associated with 30 drugs and 22 conditions by eHealthMe. Check the latest studies of Aortogram abnormal.
No report is found.
Do you take Adbry and have Aortogram abnormal?
- Check whether Aortogram abnormal is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Adbry:
- Adbry (1,899 reports)
Aortogram abnormal treatments and more:
- Aortogram abnormal (9 reports)
How severe was Aortogram abnormal and when was it recovered:
Expand to all the drugs that have ingredients of tralokinumab:
Browse all side effects of Adbry:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Aortogram abnormal:
Browse all the conditions that are associated with Aortogram abnormal:
How the study uses the data?
The study uses data from the FDA. It is based on tralokinumab (the active ingredients of Adbry) and Adbry (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Digoxin cause Ejection Fraction Abnormal? - 9 seconds ago
- Could Omeprazole cause Concussion? - 11 seconds ago
- Weight Loss in Lasix, how severe and when it was recovered? - 14 seconds ago
- Nefazodone Hydrochloride vs. Zopiclone, side effect and effectiveness comparison - 17 seconds ago
- Could Casodex cause Musculoskeletal Discomfort? - 26 seconds ago
- Could Dapsone cause Encephalitis? - 32 seconds ago
- Blood Calcium Abnormal and General Physical Health Deterioration - 33 seconds ago
- Could Cyclophosphamide cause Posterior Reversible Encephalopathy Syndrome? - 40 seconds ago
- Could Dapsone cause Abscess? - 40 seconds ago
- Drug interactions of Ceftriaxone and Epoprostenol Sodium - 46 seconds ago